Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Inflazome Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is concentrated under 1 distinct examiner and 1 distinct art unit, indicating a very focused prosecution effort at this stage. The involvement of only 1 examiner suggests that the company's current patent office interactions are focused on a single, specific point of inquiry.
The busiest examiner for this portfolio is SHTERENGARTS, SAMANTHA L, who is responsible for 1 pending office action. Because the total number of pending office actions is 1, this examiner handles the entirety of the company's active prosecution. This 1 to 1 ratio between the busiest examiner's load and the total pending actions reflects a streamlined interaction with the USPTO in the Biotechnology & Pharmaceuticals sector.
For practitioners, the presence of 1 distinct art unit means that the prosecution strategy can be highly specialized to the standards of that specific unit. With only 1 pending office action to address, the applicant can focus resources on the feedback provided by SHTERENGARTS, SAMANTHA L. This concentrated profile provides a clear and direct path for resolving the outstanding office action without the need to coordinate across multiple examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634767 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SHTERENGARTS, SAMANTHA L | 1623 | §112DPOther | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial